China
Africa
Explore chapters and articles related to this topic
Current and Future Prospects in the Treatment of Chronic Obstructive Pulmonary Disorders
Published in Suvardhan Kanchi, Rajasekhar Chokkareddy, Mashallah Rezakazemi, Smart Nanodevices for Point-of-Care Applications, 2022
Manu Sharma, Aishwarya Rathore, Sheelu Sharma, Kakarla Raghava Reddy, Veera Sadhu
A dry powder inhaler (DPI) facilitates the delivery of medicines in dry powder form to the lungs when one breathes in through the device (Figure 7.6). A DPI, instead of using a propellant to deliver medicine into the lungs, utilizes an inward breath for delivery of the medicines. They are available in single-dose and multiple-dose devices. Multiple-dose devices contain up to 200 doses. They are easy to use, spacers are not needed, and coordination between breathing and pressing the device is not required [18]. However, patients have to breathe in deeper while using a DPI compared to an MDI. Furthermore, the reproducibility of the dose is also difficult to achieve each time with a DPI. Humidity and other environmental factors also govern the efficacy of DPIs.
New Approaches from Nanomedicine and Pulmonary Drug Delivery for the Treatment of Tuberculosis
Published in Ana Rute Neves, Salette Reis, Nanoparticles in Life Sciences and Biomedicine, 2018
Joana Magalhães, Alexandre C. Vieira, Soraia Pinto, Sara Pinheiro, Andreia Granja, Susana Santos, Marina Pinheiro, Salette Reis
The aerosolization of drugs as fine powders using dry powder inhalers (DPIs) is a convenient way of delivering drugs to the lungs. Liquid formulations can also be administered through a nebulizer. Alternatively, drugs can be directly delivered to the lungs, without prior aerosolization, using an insufflator [52].
Influence of microbubbles on the production of spray-dried inhalable particles
Published in Drying Technology, 2022
Loreana Gallo, Marcos Andrés Serain, Carlos Renaudo, Eduardo López, Verónica Bucalá
The administration of drugs through the pulmonary route is becoming relevant for the treatment of lung and systemic diseases by using appropriate inhalers.[1] Among them, dry powder inhalers (DPIs) are the most commonly employed devices because they offers several advantages over other inhalation techniques, such as: ease of use, convenient portability, satisfactory pulmonary deposition via the patient respiration, easy incorporation of high mass of drugs, adequate physicochemical stability and low cost.[2] In addition, DPIs as propellant-free devices produce ten times less greenhouse effect than pressurized metered dose inhalers (propellant-driven technology).[3] The DPIs market begins in the 1960s and the adoption by pharmaceutical companies has been growing steadily due to the inhalers advantages. The DPIs market size exceeded US$16 billion in 2015 and is expected to continue growing at 5% CAGR (compound annual growth rate) until 2024.[4]